Henry SP - Search Results

1

Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.

Shemesh CS, Yu RZ, Gaus HJ, Seth PP, Swayze EE, Bennett FC, Geary RS, Henry SP, Wang Y. Shemesh CS, et al. Among authors: henry sp. Nucleic Acid Ther. 2016 Aug;26(4):223-35. doi: 10.1089/nat.2016.0607. Epub 2016 Mar 31. Nucleic Acid Ther. 2016. PMID: 27031383

2

Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.

Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Geary RS, et al. Among authors: henry sp. Anticancer Drug Des. 1997 Jul;12(5):383-93. Anticancer Drug Des. 1997. PMID: 9236854 Review. No abstract available.

3

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

Henry SP, Monteith D, Bennett F, Levin AA. Henry SP, et al. Anticancer Drug Des. 1997 Jul;12(5):409-20. Anticancer Drug Des. 1997. PMID: 9236856 Review. No abstract available.

4

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81. doi: 10.1089/oli.1.1997.7.473. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361906

5

Inhibition of coagulation by a phosphorothioate oligonucleotide.

Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Henry SP, et al. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10. doi: 10.1089/oli.1.1997.7.503. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9361909

6

Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.

Leeds JM, Henry SP, Geary R, Burckin T, Levin AA. Leeds JM, et al. Among authors: henry sp. Antisense Nucleic Acid Drug Dev. 2000 Dec;10(6):435-41. doi: 10.1089/oli.1.2000.10.435. Antisense Nucleic Acid Drug Dev. 2000. PMID: 11198927

7

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

Henry SP, Geary RS, Yu R, Levin AA. Henry SP, et al. Curr Opin Investig Drugs. 2001 Oct;2(10):1444-9. Curr Opin Investig Drugs. 2001. PMID: 11890363

8

Fomivirsen: clinical pharmacology and potential drug interactions.

Geary RS, Henry SP, Grillone LR. Geary RS, et al. Among authors: henry sp. Clin Pharmacokinet. 2002;41(4):255-60. doi: 10.2165/00003088-200241040-00002. Clin Pharmacokinet. 2002. PMID: 11978144 Review.

9

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.

Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. Geary RS, et al. Among authors: henry sp. Drug Metab Dispos. 2003 Nov;31(11):1419-28. doi: 10.1124/dmd.31.11.1419. Drug Metab Dispos. 2003. PMID: 14570775

10

Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA. Henry SP, et al. Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):359-67. doi: 10.1002/bdrb.20023. Birth Defects Res B Dev Reprod Toxicol. 2004. PMID: 15617021

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters